Corinthian Colleges, Inc. operates as a post-secondary education company. The company offers various diploma programs, as well as associate, bachelor's, and master's degrees. It also provides training program in healthcare, criminal justice, business, mechanical, trades, and information technology areas. The company's diploma curricula includes medical assisting, medical insurance billing and coding, massage therapy, dental assisting, pharmacy technician, medical administrative assisting, surgical technology, automotive and diesel technology, HVAC, plumbing, electrical, and licensed practical nursing programs. Its degree curriculum comprises business administration, accounting, paralegal, criminal justice, medical assisting, and registered nursing programs. Corinthian Colleges, Inc. also provides online programs in business, criminal justice, criminal investigations, accounting, computer information science, and paralegal. As of June 30, 2013, it operated 97 schools in 25 states of the United States and 14 schools in the province of Ontario, Canada with a total of 81,284 student enrollments under the Everest, WyoTech, and Heald brand names. The company was founded in 1995 and is based in Santa Ana, California.
dELiA*s, Inc. operates as a multi-channel retail company, primarily marketing to teenage girls in the United States. The company sells various product categories to consumers through its Website, direct mail catalogs, and retail stores. It develops, markets, and sells a collection of apparel, dresses, swimwear, footwear, outerwear, and accessories primarily for teenage girls under the dELiA*s name. As of May 3, 2014, the company operated 99 stores. It also develops, markets, and sells third-party brands. The company was founded in 1997 and is based in New York, New York.
SIGA Technologies, Inc. is engaged in the development and commercialization of pharmaceutical solutions for serious unmet medical needs and biothreats. The company's lead product is Arestvyr, an orally administered antiviral drug that targets orthopoxviruses. It is also developing dengue antiviral and anti-arenavirus drug candidates, which are in pre-clinical stage. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.
SemiLEDs Corporation develops, manufactures, and sells light emitting diode (LED) chips and LED components. Its products are used primarily for general lighting applications, including street lights and commercial, industrial, and residential lighting, as well as specialty industrial applications, such as ultraviolet (UV) applications, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, and architectural lighting applications. The company markets and sells blue, green, and UV LED and enhanced vertical LED chips under the MvpLED brand name to packagers, or distributors that sell to packaging customers in China, Taiwan, Russia, and the United States. It also packages its LED chips into LED components and sells to distributors and end-customers. SemiLEDs Corporation was incorporated in 2005 and is based in Chunan, Taiwan.
Odyssey Marine Exploration, Inc., together with its subsidiaries, is engaged in the archaeologically sensitive exploration and recovery of deep-ocean shipwrecks worldwide. Its shipwreck projects include various activities, such as research of historical records and academic materials; search operations; archaeological pre-disturbance survey, and archaeological excavation and recovery; conservation, recording, documentation, and publication/exhibition; surgical removal of deck plates or ship structures; cargo salvage; and commercial monetization of recovered cargo. The company also conducts deep-ocean mineral exploration; and sells coins, bullion, and other mass-produced cargo to collectors, as well as cultural collections of artifacts to museums and other institutions. Odyssey Marine Exploration, Inc. was founded in 1986 and is headquartered in Tampa, Florida.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.
Spherix Incorporated operates as an intellectual property company that owns patented and unpatented intellectual properties. The company owns approximately 330 patents and patent applications. Its patent portfolio includes the U.S. and foreign patents and pending patent applications in the wireless communications and telecommunication sectors, including data, optical and voice technology, antenna technology, Wi-Fi, base station functionality, and cellular, as well as patents related to artificial sweetener and prescription refill technology. The company was founded in 1967 and is based in Tysons Corner, Virginia.
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Sorrento Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. Its lead product candidate, Cynviloq, is a micellar diblock copolymeric paclitaxel formulation currently approved and marketed in various countries, including South Korea, for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I or III trials for MBC, and Phase I or II trials in NSCLC, Ovarian, Bladder, and Pancreatic cancers. The company is also developing resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company is also developing antibody drug conjugates and recombinant intravenous immunoglobulin (rIVIG) for the treatment of certain auto-immune diseases, as well as immunodeficiencies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
China Gerui Advanced Materials Group Limited operates as a contract manufacturer of cold-rolled narrow strip steel products in the People's Republic of China and internationally. The company converts steel manufactured by third parties into thin steel sheets and strips. It primarily serves food and industrial packaging, construction and household decorations materials, electrical appliances, and telecommunications wires and cables industries. The company sells its products directly to manufacturers or through distributors. The company was formerly known as Golden Green Enterprises Limited and changed its name to China Gerui Advanced Materials Group Limited in December 2009. China Gerui Advanced Materials Group Limited is based in Zhengzhou, the People's Republic of China.